Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 112 posts found.

biogen_idec_hillerod_2008

Biogen signs $2 billion partnership deal with UPenn for gene therapies

May 17, 2016
Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research

Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …

News
biogen_logo

Sobi, Biogen’s haemophilia B therapy gets European approval

May 13, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi

Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …

News

Biogen to spin off its haemophilia business

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off

Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …

News
biogen_austria_238

EMA recommends Biogen’s MS treatment Zinbryta

May 3, 2016
Research and Development, Sales and Marketing Biogen, CHMP, EMA, daclizumab, zinbryta

The Committee for Medicinal Products for Human Use (CMHP) has recommended the granting of a marketing authorisation for Zinbryta (daclizumab) …

News
biogen_austria_238

New head of R&D at Biogen

April 27, 2016
Research and Development Biogen, Pfizer, R&D, erhlers, michael, michael erhlers, research and development

Biogen (NASDAQ: BIIB) has announced the appointment of Dr Michael Ehlers as executive vice president, research and development. His role …

Appointment
biogen_logo

Biogen Q1 profits rise boosted by Tecfidera sales

April 22, 2016
Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …

News
samsung

Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis

Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …

News
Biogen image

Sobi and Biogen’s haemophilia A treatment EU-approved

November 27, 2015
Sales and Marketing Biogen, elocta, haemophilia a, sobi

Elocta, the haemophilia A treatment developed by the Swedish Orphan Biovitrum (Sobi) and Biogen, has received European Commission approval as …

News
mgt_kingsley

Executive vice president Tony Kingsley leaves Biogen

October 22, 2015
Biogen, John Cox, Tony Kingsley

Biogen has begun the search for a replacement for Tony Kingsley, former executive vice president of global commercial operations.Kingsley will …

Appointment
biogen_logo

Revenues up at Biogen – but job losses planned

October 22, 2015
Biogen, financial results, job losses, redundancies

Despite lower than predicted sales of its top-selling products, Biogen has achieved $2.8 billion in revenues in the third quarter …

News
Biogen image

Biogen’s natalizumab fails Phase III endpoints

October 21, 2015
Biogen, multiple sclerosis

Biogen’s natalizumab has failed to achieve clinical endpoints in a late-stage study to prove the drug’s potential in patients with …

News
WHO flag

Novartis and Biogen launch drug access programmes in developing countries

October 15, 2015
Manufacturing and Production, Sales and Marketing Biogen, Novartis, access, aid, corporate social responsibility, csr, humanitarian aid

Novartis and Biogen have begun new campaigns aimed at increasing access to medicines in developing countries.  The Swiss firm has …

News
Alzheimer's research

Neurimmune kicks off late-stage Alzheimer’s study

September 9, 2015
Research and Development Alzheimer's disease, Biogen, Neurimmune, aducanumab, neurology

Neurimmune and its development partner Biogen are beginning a Phase III study of the companies’ potential Alzheimer’s treatment aducanumab.  The …

News
alzheimers_brain

Lilly, Biogen and Roche debut Alzheimer’s disease drug results

July 22, 2015
Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly

Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …

News

Biogen to build billion-dollar plant in Switzerland

July 7, 2015
Manufacturing and Production Alzherimer's disease, Biogen, Biogen IDEC, MS, Switzerland, manufacturing, multiple sclerosis

Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal with the future demand for …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023